Investor
The California-based company will use the investment to scale product innovation and advance integrations with enterprise partners.
The company saw its stock price drop upon release of its first-quarter earnings.
Andy Molnar, CEO of the Digital Therapeutics Alliance, discusses the market for digital therapeutics after Pear Therapeutics declared bankruptcy.
The company also released its Q1 2023 earnings, showing increased revenue of $311.1 million with a net loss of $63.2 million.
Oura said the deal could provide new opportunities in payments and data security.
The startup plans to use AI-backed retinal imaging to find early signs of disease based on tech from Australian company Eyetelligence.
In a letter to employees, CEO Ayub Khattak said the diagnostics company's new initiatives are "progressing well but are still early in terms of revenue generation."
Boehringer Ingelheim and Click Therapeutics initiate clinical trial on PDTx treatment for schizophrenia and Akili's EndeavorRx shows promise for adults with ADHD.
The company reported a larger net loss in the first quarter that included a $330.3 million noncash goodwill impairment charge.
Diabetes management company Hygieia extended its Series B round, and Autonomize AI, a workflow platform for healthcare and life sciences, also announced funding.